What Holmusk does

Holmusk is a Singapore-headquartered (founded 2015) healthcare data and technology company that builds real-world evidence infrastructure for behavioral health and neuropsychiatry. Its flagship platform, NeuroBlu, combines a proprietary database of over 46 million de-identified patient lives drawn from longitudinal electronic health records across 30+ U.S. health systems and 50 states, with analytics software and clinical expertise services. The database is enriched using the company's proprietary BERT-based natural language processing models — the first developed specifically for behavioral health — which extract over 300 psychiatry-specific data labels (e.g., anhedonia, suicidality, CGI-S scores) from unstructured clinical notes. The company also operates MaST, a clinical decision support tool deployed across 8 UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Holmusk generates revenue primarily through subscription-based licensing of the NeuroBlu Database and NeuroBlu Analytics software to enterprise customers, supplemented by professional services where its clinical and data science teams guide study design and execution. Its primary customer segments are life sciences and biopharma companies (used by 5 of the top 15 biopharma with behavioral health pipelines for trial design, HEOR, and market access), payers and healthcare providers (care management and high-risk patient identification), academic and research institutions, and government/regulators. Distribution is sales-led with direct enterprise engagement, complemented by strategic partnerships — notably with Veradigm, Novartis, Optum Ventures, and Northwell Holdings — that simultaneously provide capital, data assets, and channel access into the healthcare ecosystem.

The company is privately held and has raised approximately $106M+ in venture funding across multiple rounds, including a $45M Series B led by Veradigm in January 2023. It maintains operating offices in Singapore (HQ), New York (U.S. HQ), London, and Basel, and has grown primarily through organic product expansion plus targeted acquisitions (MindLinc in 2016, Otsuka Health Solutions in 2021, and the MaST business). Holmusk's strategy is to consolidate fragmented behavioral health data into a research-grade real-world evidence platform that supports both drug development and clinical decision-making, with a recent push into neurology and Alzheimer's biomarker data extending its addressable market beyond pure psychiatry.

Name

Holmusk

Legal name

Holmusk USA, Inc.

Website

https://holmusk.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Holmusk is a Singapore-based healthcare data and technology company that operates NeuroBlu, the largest real-world evidence platform for behavioral health and neuropsychiatry. It serves life sciences companies, payers, and providers with de-identified longitudinal patient data, NLP-enriched analytics, and clinical decision support tools.

Ownership category

akta.pro rank

Product category

Real-World Evidence Analytics Software

NAICS

Research and Development in the Social Sciences and Humanities (541720), Other Scientific and Technical Consulting Services (541690)

SIC

Services-Misc Health & Allied Services, Nec (8090), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industry

Psychiatry & Medication Management Platforms (HLALAEAB)

Keywords

• Real-world evidence
• Behavioral health data
• Clinical decision support
• Electronic health records
• Natural language processing

Headquarters

HQ city

Singapore

HQ country

Singapore

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. NeuroBlu Database Access: Licensing of research-grade real-world evidence database to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.
2. NeuroBlu Analytics Software: User-friendly data analytics software with no-code analytics capabilities and pre-designed study templates. Provides self-service access to database insights.
3. Clinical Expertise Services: Collaborative analysis services where Holmusk's team of clinical and data science experts guide customers through design and execution of end-to-end studies tailored to their organization's needs.
4. MaST Clinical Decision Support: Clinical decision support tool (MaST) deployed to NHS Mental Health Trusts in the UK for crisis risk prediction and caseload management.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Holmusk builds and licenses the NeuroBlu real-world evidence platform for neuropsychiatry, comprising a de-identified longitudinal EHR database of 46+ million behavioral and neurological health patients, no-code analytics software, and clinical-expert study services. The company also offers MaST, a clinical decision support tool deployed across UK NHS Mental Health Trusts for crisis risk prediction, and HolCare EHR+, a psychiatry-specific electronic health record with integrated measurement-based care.

Product overview

Holmusk offers a unified platform-plus-modules architecture centered on NeuroBlu, its flagship real-world evidence platform for neuropsychiatry. The core NeuroBlu platform comprises three integrated components: the NeuroBlu Database (a proprietary database of de-identified EHR data from 46+ million patients), NeuroBlu Analytics (no-code analytics software with pre-designed study templates), and NeuroBlu Services (expert consulting for study design and execution). The company also offers MaST, a clinical decision support tool with predictive crisis-risk algorithms deployed across UK NHS Mental Health Trusts, and HolCare EHR+, a psychiatry-specific EHR with integrated measurement-based care. MindLinc, an acquired psychiatry-specific EHR product, serves as a foundational data source for the NeuroBlu Database. The portfolio enables researchers to access longitudinal behavioral health data, conduct observational studies, and generate real-world evidence for drug development and clinical care improvement.

Differentiator

Problem solved

Functional benefit

Brands

• NeuroBlu: Flagship real-world evidence platform for behavioral health providing database access, analytics software, and clinical expertise services
• NeuroBlu Database
• NeuroBlu Analytics
• MaST
• MindLinc
• HolCare EHR+
• The Hol Picture

Products and services

• NeuroBlu Database The industry's largest real-world evidence database for behavioral health containing de-identified EHR data from over 46 million patients across 50 U.S. states with 20+ years of longitudinal data spanning inpatient and outpatient sites. Licensed to life sciences, biopharma, and biotech organizations for observational study design and evidence-generation workflows.
• NeuroBlu Analytics User-friendly data analytics software with no-code analytics capabilities and pre-designed study templates that enables researchers to access insights from the NeuroBlu Database, independently explore the data, and build their own projects.
• NeuroBlu Services Clinical and data science expert services that collaborate with clients to design and execute end-to-end studies tailored to their organization's needs within the NeuroBlu platform.
• MaST (Management and Supervision Tool) Clinical decision support tool used in UK NHS Mental Health Trusts that leverages data visualization and predictive analytics via a Risk-of-Crisis algorithm to prioritize individuals at risk of mental health crisis and improve caseload management. Implemented across eight NHS Mental Health Trusts.
• HolCare EHR+ Psychiatry-specific electronic health record platform with fully integrated measurement-based care designed to help make data capture easier and more complete for behavioral health clinicians.
• MindLinc Psychiatry-specific EHR/database product originally developed separately and later acquired; serves as a foundation for the NeuroBlu Database with most patient records containing Clinical Global Impressions Scale (CGI-S) measures.

Quantifiable outcome

• 72% of mental health crises identified as high risk in advance using MaST Risk-of-Crisis algorithm
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Three partnerships are on record, tiered strategic, core and minor.

• VeradigmstrategicStrategic or Co-development Partner · 2 October 2023Holmusk and Veradigm announced a new phase of strategic collaboration to enhance veterinary health outcomes using real-world data. The collaboration will expand Holmusk's NeuroBlu Database with millions of behavioral health patients' data from Veradigm, aiming to improve research and evidence generation in behavioral health.
• NHS Mental Health TrustscoreStrategic or Co-development PartnerPartnership with NHS Mental Health Trusts in the UK for deployment of MaST (Management and Supervision Tool) clinical decision support system. Currently implemented across 8 NHS Mental Health Trusts as part of community mental health transformation initiative.
• Academic Medical InstitutionsminorStrategic or Co-development PartnerPartnerships with academic medical institutions for expanding the NeuroBlu Database and adding new behavioral health assessments and scales.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• ConcertAI: ConcertAI is a real-world evidence and AI platform serving life sciences and providers, with deep therapeutic-area focus. It competes head-to-head with Holmusk for biopharma RWE contracts, including in oncology and emerging specialty areas, and has raised substantially more capital.
• Aetion: Aetion provides an RWE analytics platform (Aetion Evidence Platform) used by biopharma and regulators to evaluate treatment effectiveness from real-world data. It directly competes with NeuroBlu Analytics for life-sciences RWE budget, especially for regulatory-grade submissions.
• Tempus Labs: Tempus combines molecular and clinical real-world data with AI analytics to support precision medicine, primarily oncology but expanding into neuropsychiatry and neurology. It overlaps with Holmusk's combination of large-scale clinical data and AI analytics for life-sciences research.
• Komodo Health: Komodo Health operates a large healthcare data map and analytics platform for life sciences, payers, and providers, with broad therapeutic coverage. It is a direct comparable in the RWE infrastructure layer, competing for similar biopharma and payer contracts as Holmusk.

Broad incumbents

• Flatiron Health: Flatiron Health (acquired by Roche) is a leading oncology-focused RWE platform serving biopharma with de-identified EHR data and analytics. While primarily oncology, it sets the standard for specialty RWE platforms and competes for similar customer mindshare and partnerships Holmusk targets.
• IQVIA: IQVIA is the largest global clinical and real-world evidence vendor serving biopharma across all therapeutic areas. As a broad incumbent with massive data assets, it competes with Holmusk for life-sciences RWE budgets and could replicate or acquire specialty behavioral health RWE capabilities.

Emerging players

• Datavant: Datavant focuses on health data connectivity and de-identification, enabling privacy-preserving linking of clinical datasets. Its ecosystem approach overlaps with Holmusk's data-partnership model and competes for the same underlying health-system data partnerships.
• Mendel: Mendel applies NLP to unstructured clinical text to make EHR data research-ready for life sciences. It competes directly with Holmusk's NLP enrichment layer as a technology alternative for transforming clinical notes into research-grade variables.
• Eleos Health: Eleos Health provides AI-powered clinical documentation and decision support for behavioral health providers. It competes with Holmusk's MaST offering in the behavioral health clinical decision-support market, although from a documentation/capture angle rather than data aggregation.

Others

• Veradigm (Allscripts spinoff): Veradigm is both Holmusk's lead investor and data partner, providing EHR-sourced patient cohorts that feed the NeuroBlu Database. While not a direct competitor, the relationship is strategic and creates a coupled ecosystem dynamic unique among Holmusk's peer set.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/holmusk
• LinkedInlinkedin.com/company/holmusk

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Subsidiaries4 records

Funding overview

Funding rounds6 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Holmusk